Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact - 25/07/20
Doi : 10.1016/j.jinf.2020.04.017
Fabrizio Cantini a, ⁎ 
, Laura Niccoli a, Daniela Matarrese b , Emanuele Nicastri c , Paolo Stobbione e , Delia Goletti c, d
, Laura Niccoli a, Daniela Matarrese b , Emanuele Nicastri c , Paolo Stobbione e , Delia Goletti c, d a Rheumatology Department, Azienda USL Toscana Centro, Hospital of Prato, Piazza Ospedale 1
b Azienda USL Toscana Centro, Hospital of Prato, Italy
c National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Via Portuense, 292, Rome 00149, Italy
d Department of Epidemiology and Preclinical Research, “L. Spallanzani” National Institute for Infectious Diseases (INMI), IRCCS, Via Portuense 292, 00149 Rome, Italy
e AOS Antonio e Biagio e C. Arrigo, Rheumatology Unit – Alessandria, Italy
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Baricitinib at 4 mg/day/orally was given to 12 patients with moderate COVID-19. |
• | In baricitinib-treated patients no adverse events were recorded, after 2 weeks. |
• | Clinical and respiratory parameters significantly improved at 2 weeks. |
• | None of the baricitinib-treated patients required admission to ICU. |
• | Proper control group was missing; this is required to demonstrate the efficacy. |
Graphical abstract |
Plan
© 2020
Publié par Elsevier Masson SAS.
Vol 81 - N° 2
P. 318-356 - août 2020 Retour au numéro
Article précédent
- Evaluation of MucorGenius® mucorales PCR assay for the diagnosis of pulmonary mucormycosis
- Hélène Guegan, Xavier Iriart, Marie-Elisabeth Bougnoux, Antoine Berry, Florence Robert-Gangneux, Jean-Pierre Gangneux
- Bayesian phylodynamic inference on the temporal evolution and global transmission of SARS-CoV-2
- Jianguo Li, Zhen Li, Xiaogang Cui, Changxin Wu
Bienvenue sur EM-consulte, la référence des professionnels de santé.